Results 61 to 70 of about 1,506 (115)

Post‐translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases

MedComm, Volume 7, Issue 4, April 2026.
Posttranslational modifications (PTMs) serve as rapid and reversible molecular switches that reshape protein activity, stability, and interactomes, thereby governing virtually all physiological cues ranging from signal transduction to epigenetic memory. Mass spectrometry‐based proteomics has substantially expanded our understanding of PTM emergence and
Shuning Zhang, Jingmin Li, Meihuan Chen, Hailong Huang   +3 more
wiley   +1 more source

Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review

Frontiers in Oncology
Pralsetinib and selpercatinib have been approved as specific tyrosine kinase inhibitors (TKIs) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) fusion and mutation.
Kaidiriye Setiwalidi, Yimeng Li, Yuyan Ma, Zhanpeng Hao, Yujia Zhao, Yuxin Zhang, Xuan Liang, Tao Tian, Zhiping Ruan, Yu Yao, Xiao Fu   +10 more
doaj   +1 more source

Medullary thyroid carcinoma and RET molecular testing: A virtual tumor board on clinical decision‐making

CA: A Cancer Journal for Clinicians, Volume 76, Issue 3, May/June 2026.
Lucas Kallas‐Silva, Victor Alexandre dos Santos Valsecchi, Ana O. Hoff, Evelin Cavalcante Farias, Rui Monteiro de Barros Maciel, Rachel Riera, Laura Sterian Ward, Lucas Leite Cunha   +7 more
wiley   +1 more source

A case of neoadjuvant targeted therapy with pralsetinib for locally advanced lung adenocarcinoma with RET fusion mutation

Journal of Cardiothoracic Surgery
This case report details the successful treatment of a 68-year-old male patient with locally advanced RET-rearranged lung adenocarcinoma using neoadjuvant pralsetinib.
Wang Chunmao, Cheng Haijie, Wang Zitong, Yang Zhi   +3 more
doaj   +1 more source

A Locally Advanced NSCLC Patient Harboring a Rare KIF13A-RET Fusion Benefited from Pralsetinib: A Case Report

Current Oncology
The application of adjuvant treatment has significantly enhanced the survival of patients with resectable non-small cell lung cancer (NSCLC) carrying driver gene mutations.
Zenghao Chang, Tengfei Zhu, Hao Jiang, Wei Ou, Siyu Wang   +4 more
doaj   +1 more source

Abstracts

Cancer Science, Volume 117, Issue S1, Page 1-2148, January 2026.
wiley   +1 more source

LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC

Lung Cancer: Targets and Therapy
Alexandria TM Lee,1 Sai-Hong Ignatius Ou2 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, 92868, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USACorrespondence: Sai-Hong Ignatius Ou ...
Lee ATM, Ou SI
doaj  

The combination of pralsetinib and bevacizumab enhances antitumor activity against KIF5B-RET lung cancer via PI3K/AKT pathway. [PDF]

J Thorac Dis
Wang X, Yuan G, Cong L, Song Z, Lin L, Cao Z.   +5 more
europepmc   +1 more source

Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Frontiers in Oncology, 2022
Sha-Sha Wang, Fang Wang, Zhen Zeng, Fang Gao, Huan-Huan Liu, Hui-Na Wang, Yi Hu, Hai-Feng Qin   +7 more
doaj   +1 more source

Targeted therapies in the management of advanced medullary thyroid cancer. [PDF]

Oncologist
Arain HA, Izhar A, Caretti R, Chen H, Vodopivec DM.   +4 more
europepmc   +1 more source